The Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

It's been a good week for Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) shareholders, because the company has just released its latest second-quarter results, and the shares gained 5.2% to ₹3,818. Results overall were respectable, with statutory earnings of ₹17.45 per share roughly in line with what the analysts had forecast. Revenues of ₹33b came in 2.8% ahead of analyst predictions. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

After the latest results, the 29 analysts covering Torrent Pharmaceuticals are now predicting revenues of ₹130.6b in 2026. If met, this would reflect a reasonable 6.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to swell 15% to ₹72.69. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹129.9b and earnings per share (EPS) of ₹72.43 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

View our latest analysis for Torrent Pharmaceuticals

There were no changes to revenue or earnings estimates or the price target of ₹4,010, suggesting that the company has met expectations in its recent result. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Torrent Pharmaceuticals analyst has a price target of ₹4,380 per share, while the most pessimistic values it at ₹3,530. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Torrent Pharmaceuticals' past performance and to peers in the same industry. It's clear from the latest estimates that Torrent Pharmaceuticals' rate of growth is expected to accelerate meaningfully, with the forecast 14% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 9.4% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 11% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Torrent Pharmaceuticals is expected to grow much faster than its industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at ₹4,010, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Torrent Pharmaceuticals going out to 2028, and you can see them free on our platform here..

It is also worth noting that we have found 1 warning sign for Torrent Pharmaceuticals that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.